Semaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activities
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to ...